Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease

Circ Cardiovasc Imaging. 2014 Mar;7(2):274-81. doi: 10.1161/CIRCIMAGING.113.000785. Epub 2014 Feb 6.

Abstract

Background: The incretin hormone, glucagon-like peptide-1, promotes myocardial glucose uptake and may improve myocardial tolerance to ischemia. Endogenous glucagon-like peptide-1 (7-36) is augmented by pharmacological inhibition of dipeptidyl peptidase-4. We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protected against ischemic left ventricular dysfunction during dobutamine stress in patients with type 2 diabetes mellitus and coronary artery disease.

Methods and results: A total of 19 patients with type 2 diabetes mellitus underwent dobutamine stress echocardiography with tissue Doppler imaging on 2 separate occasions: the first (control) while receiving oral hypoglycemic agents, and the second after the addition of sitagliptin (100 mg once daily) for ≈4 weeks. Sitagliptin increased plasma glucagon-like peptide-1 (7-36) levels and, at peak stress, enhanced both global (ejection fraction, 70.5±7.0 versus 65.7±8.0%; P<0.0001; mitral annular systolic velocity, 11.7±2.6 versus 10.9±2.3 cm/s; P=0.01) and regional left ventricular function, assessed by peak systolic velocity and strain rate in 12 paired, nonapical segments. This was predominantly because of a cardioprotective effect on ischemic segments (strain rate in ischemic segments, -2.27±0.65 versus -1.98±0.58 s(-1); P=0.001), whereas no effect was seen in nonischemic segments (-2.19±0.48 versus -2.18±0.54 s(-1); P=0.87). At 30 minutes recovery, dipeptidyl peptidase-4 inhibition mitigated the postischemic stunning seen in the control scan.

Conclusions: The addition of dipeptidyl peptidase-4 inhibitor therapy with sitagliptin to the treatment regime of patients with type 2 diabetes mellitus and coronary artery disease is associated with a sustained improvement in myocardial performance during dobutamine stress and a reduction in postischemic stunning.

Clinical trial registration: URL: http://www.isrctn.org. Unique identifier ISRCTN61646154.

Keywords: coronary disease; diabetes mellitus; dipeptidyl-peptidase IV inhibitors; echocardiography, stress; glucagon-like peptide-1.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Coronary Angiography
  • Coronary Artery Disease / complications*
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / drug therapy
  • Diabetes Mellitus, Type 2 / complications*
  • Dipeptidyl Peptidase 4 / drug effects
  • Dipeptidyl Peptidase 4 / metabolism*
  • Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
  • Echocardiography, Doppler
  • Echocardiography, Stress / methods
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Glucagon-Like Peptide 1
  • Heart Ventricles / diagnostic imaging
  • Heart Ventricles / physiopathology*
  • Humans
  • Male
  • Myocardial Ischemia / complications*
  • Myocardial Ischemia / diagnosis
  • Myocardial Ischemia / drug therapy
  • Pilot Projects
  • Pyrazines / administration & dosage*
  • Sitagliptin Phosphate
  • Stroke Volume / drug effects
  • Treatment Outcome
  • Triazoles / administration & dosage*
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Dysfunction, Left / prevention & control*

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Pyrazines
  • Triazoles
  • Glucagon-Like Peptide 1
  • Dipeptidyl Peptidase 4
  • Sitagliptin Phosphate

Associated data

  • ISRCTN/ISRCTN61646154